Home › Research › Treatments
Trial of Solanezumab for Mild Dementia Due to Alzheimer's Disease
Honig LS, Vellas B, Woodward M, Boada M, Bullock R, Borrie M, Hager K, Andreasen N et al.. The New England journal of medicine, 2018-01-01
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Background Alzheimer's disease is characterized by amyloid-beta (Aβ) plaques and neurofibrillary tangles. The humanized monoclonal antibody solanezumab was designed to increase the clearance from the brain of soluble Aβ, peptides that may lead to toxic effects in the synapses and precede the deposition of fibrillary amyloid. Methods We conducted a double-blind, placebo-controlled, phase 3 trial involving patients with mild dementia due to Alzheimer's disease, defined as a Mini-Mental State Examination (MMSE) score of 20 to 26 (on a scale from 0 to 30, with higher scores indicating better cognition) and with amyloid deposition shown by means of florbetapir positron-emission tomography or Aβ1-42 measurements in cerebrospinal fluid.
What this study adds
Evidence grade: Low
This is a trial of 2,129 participants. This double-blind, placebo-controlled phase 3 trial tested the humanized monoclonal antibody solanezumab, designed to increase clearance of soluble Aβ from the brain, in patients with mild dementia due to Alzheimer's disease. Participants had MMSE scores of 20 to 26 and amyloid deposition shown by florbetapir positron-emission tomography or Aβ1-42 measurements in cerebrospinal fluid.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Honig, L. S., Vellas, B., Woodward, M., Boada, M., Bullock, R., Borrie, M., et al. (2018). Trial of Solanezumab for Mild Dementia Due to Alzheimer's Disease. The New England journal of medicine. https://doi.org/10.1056/nejmoa1705971
Vancouver
Honig LS, Vellas B, Woodward M, Boada M, Bullock R, Borrie M, et al. Trial of Solanezumab for Mild Dementia Due to Alzheimer's Disease. The New England journal of medicine. 2018. doi:10.1056/nejmoa1705971. PMID: 29365294.
BibTeX
@article{honig2018-29365294,
author = {Honig, L. S. and Vellas, B. and Woodward, M. and Boada, M. and Bullock, R. and Borrie, M. and Hager, K. and Andreasen, N. and others},
title = {{Trial of Solanezumab for Mild Dementia Due to Alzheimer's Disease}},
journal = {The New England journal of medicine},
year = {2018},
doi = {10.1056/nejmoa1705971},
pmid = {29365294},
url = {https://doi.org/10.1056/nejmoa1705971}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- The humanized monoclonal antibody solanezumab was designed to increase the clearance from the brain of soluble Aβ, peptides that may lead to toxic effects in the synapses and precede the deposition of fibrillary amyloid.
- Methods We conducted a double-blind, placebo-controlled, phase 3 trial involving patients with mild dementia due to Alzheimer's disease, defined as a Mini-Mental State Examination (MMSE) score of 20 to 26 (on a scale from 0 to 30, with higher scores indicating better cognition) and with amyloid deposition shown by means of florbetapir positron-emission tomography or Aβ1-42 measurements in cerebrospinal fluid.
- Patients were randomly assigned to receive solanezumab at a dose of 400 mg or placebo intravenously every 4 weeks for 76 weeks.
- The primary outcome was the change from baseline to week 80 in the score on the 14-item cognitive subscale of the Alzheimer's Disease Assessment Scale (ADAS-cog14; scores range from 0 to 90, with higher scores indicating greater cognitive impairment).
Why it matters
This double-blind, placebo-controlled phase 3 trial tested the humanized monoclonal antibody solanezumab, designed to increase clearance of soluble Aβ from the brain, in patients with mild dementia due to Alzheimer's disease. Participants had MMSE scores of 20 to 26 and amyloid deposition shown by florbetapir positron-emission tomography or Aβ1-42 measurements in cerebrospinal fluid.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Study designclinical trial
- Participants2,129
- Evidence strengthLow
How this study scored 82/100
Published in a top-tier journal, and it is a large phase 3 trial. Scored zero for effect reported because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 10 / 10 | Tier 1 — top-tier general journal (The New England journal of medicine) |
| Journal's citation record | 4 / 4 | New England Journal of Medicine: journal h-index 1,505 (OpenAlex, 2026-10-29) |
| Study design | 11 / 12 | A large phase 3 trial (from PubMed type “Clinical Trial, Phase III”) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 2 / 5 | 2018 — within 10 year(s) of the newest study here |
| Sample size | 3 / 4 | 2,129 participants |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 2 / 2 | Randomized and blinded or placebo-controlled (as stated in the record) |
| Times cited | 7 / 7 | Cited 1,047 times (OpenAlex, 2026-10-10) |
| Citations per year | 5 / 5 | 104.7 citations a year over 10 year(s) since 2018 |
| Impact for its field and year | 6 / 6 | Cited 78.3× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 4 / 6 | Cited by 58 other studies in this library |
| Still being cited | 4 / 4 | Cited 260 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 3 / 4 | Last-listed author Eric Siemers: h-index 56 (OpenAlex, whole career) |
| Institution's track record | 2 / 3 | Inserm: institution h-index 1,988 (OpenAlex) |
| Multicenter collaboration | 3 / 3 | OpenAlex lists 18 institution(s) in 9 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 29365294) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Total | 82 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1056/nejmoa1705971
- PubMed: 29365294
- Original source →
- Free full text: New England Journal of Medicine →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 13.
Later studies that cite this one
58 studies in the alzhub library list this one in their references. Showing the 8 highest-scoring.
Related studies in Treatments from nearby years
Also tagged “trial”
783 studies in the library carry the topic tag “trial”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 783 tagged studies.